Anti-CD123 CAR-T therapy combined with autologous SCT and venetoclax maintenance in refractory BPDCN ineligible for allogeneic transplantation: a case report and review of the literature
Fan Yang, Danyang Li, Yang Lei, Rui Liu, Zhonghua Fu, Lixia Ma, Biping Deng, Xiaoyan Ke, Kai Hu · 2026
Read Anti-CD123 CAR-T therapy combined with autologous SCT and venetoclax maintenance in refractory BPDCN ineligible for allogeneic transplantation: a case report and review of the literature by Fan Yang, Danyang Li, Yang Lei, Rui Liu, Zhonghua Fu, Lixia Ma, Biping Deng, Xiaoyan Ke, Kai Hu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13473410.txt.
Description
Yang and colleagues present a 2026 case report and literature review of a triple strategy against a rare, aggressive blood cancer, blastic plasmacytoid dendritic cell neoplasm. The patient, a 55-year-old man with relapsed disease in his nervous system, had no matched donor for the standard donor transplant. After chemotherapy he reached a full metabolic response, though trace disease remained in his marrow.
He then received high-dose conditioning and his own stem cells back, followed by CAR T cells engineered against CD123, a marker on the cancer, and maintenance with the drug venetoclax. The course included a severe immune reaction, which was managed. Stacking three consolidations aims at durability without a donor. One pioneering case cannot set a standard, but it maps a route for patients who relapse with no donor available.
Catalog record
| CREATOR | Fan Yang, Danyang Li, Yang Lei, Rui Liu, Zhonghua Fu, Lixia Ma, Biping Deng, Xiaoyan Ke, Kai Hu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |